Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Adebrelimab Plus Dalpiciclib in HPV-negative HNSCC
NCT06199271Phase 2Not yet recruiting
- Start
- Jan 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of adebrelimab, dalpiciclib in head and neck squamous cell carcinoma (HNSCC). Planned start Jan 2024; status: not yet recruiting.
02
Drugs
adebrelimabdalpiciclib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06199271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06199271.